Skip to Content

Generic VisionBlue Availability

VisionBlue is a brand name of trypan blue ophthalmic, approved by the FDA in the following formulation(s):

VISIONBLUE (trypan blue - solution;ophthalmic)

  • Manufacturer: DORC
    Approval date: December 16, 2004
    Strength(s): 0.06% [RLD]

Has a generic version of VisionBlue been approved?

No. There is currently no therapeutically equivalent version of VisionBlue available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of VisionBlue. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Methods for visualizing the anterior lens capsule of the human eye
    Patent 6,367,480
    Issued: April 9, 2002
    Inventor(s): Minas Theodore; Coroneo

    Use of trypan blue in the manufacture of a composition to enhance the visualisation of the anterior lens capsule of the eye during removal of a cataractous lens and lens replacement procedures is described. Also described are methods for the visualisation of the anterior lens capsule and processes for cataract treatment.

    Patent expiration dates:

    • October 26, 2019
      ✓ 
      Patent use: A METHOD OF APPLYING TRYPAN BLUE ONTO AN OUTER SURFACE OF THE ANTERIOR LENS CAPSULE TO FACILITATE REMOVAL OF THE LENS SUBSTANCE
  • Use of a vital dye for facilitating surgical procedures for cataract extraction
    Patent 6,720,314
    Issued: April 13, 2004
    Inventor(s): Gerrit Reinold J.; Melles

    Methods for performing a capsulorhexis are disclosed wherein a dye is used to stain a lens capsule of an eye. The dye is capable of staining tissue without diffusing through the tissue. Compositions including dyes that are useful in the methods are also disclosed.

    Patent expiration dates:

    • May 7, 2019
      ✓ 
      Patent use: A METHOD OF APPLYING TRYPAN BLUE ONTO AN OUTER SURFACE OF THE ANTERIOR LENS CAPSULE TO FACILITATE REMOVAL OF THE LENS SUBSTANCE

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide